Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amibegron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 known ✓ | P13945 | 12/20 | 0.91 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amibegron SCHEMBL8765764 | 1.00 | ADRB3 (0.91) | ADRB3ADRB1 | |
| Amibegron SCHEMBL2052478 | 1.00 | ADRB3 (0.91) | ADRB3ADRB1 | |
| Amibegron SCHEMBL3898164 | 1.00 | ADRB3 (0.91) | ADRB3ADRB1 | |
| Amibegron SCHEMBL29373533 | 1.00 | ADRB3 (0.91) | ADRB3ADRB1 | |
| Amibegron SCHEMBL3824162 | 1.00 | ADRB3 (0.91) | ADRB3ADRB1 | |
| Amibegron SCHEMBL5200899 | 1.00 | ADRB3 (0.91) | ADRB3ADRB1 | |
| Amibegron SCHEMBL9006793 | 1.00 | ADRB3 (0.91) | ADRB3ADRB1 | |
| Amibegron SCHEMBL3908665 | 1.00 | ADRB3 (0.91) | ADRB3ADRB1 | |
| Amibegron SCHEMBL9317343 | 0.99 | ADRB3 (0.89) | ADRB3ADRB1 | |
| Amibegron SCHEMBL3897916 | 0.99 | ADRB3 (0.89) | ADRB3ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0966276-B1 | USE OF BETA-3 ADRENERGIC RECEPTOR AGONISTS FOR PREPARING WOUND-HEALING PHARMACEUTICALS | SANOFI SYNTHELABO (FR) | 2003-12-10 | — | — | EP | claimed |
| US-6235793-B1 | IN DIABETIC MAMMALS | SANOFI-SYNTHELABO (FR) | 2001-05-22 | — | — | US | claimed |
| EP-0966276-A1 | USE OF AGONISTS OF ADRENERGIC BETA-3 RECEPTORS FOR PREPARING WOUND-HEALING MEDICINES | SANOFI-SYNTHELABO (FR) | 1999-12-29 | — | — | EP | claimed |
| WO-1998031357-A1 | USE OF AGONISTS OF ADRENERGIC BETA-3 RECEPTORS FOR PREPARING WOUND-HEALING MEDICINES | SANOFI-SYNTHELABO (FR) | 1998-07-23 | — | — | WO | claimed |
| EP-0403360-B1 | Use of phenylethanolamines for the preparation of a medicament for treating ophthalmologic disorders | SANOFI SA (FR) | 1996-10-16 | — | — | EP | claimed |
| EP-0303546-B1 | O-alkylation process for N-(hydroxy)aralkyl phenyl ethanol amines | SANOFI SA (FR) | 1994-12-28 | — | — | EP | claimed |
| US-5347037-A | (RR) and (RS stereoisomers of N-(7-ethoxycarbonylmethoxy-1,2,3,-tetrahydronaphth-2-yl)-2-(3-chlorophenyl)-2-hydroxyethanamine and their pharmaceutically acceptable salts | SANOFI (FR) | 1994-09-13 | — | — | US | claimed |
| EP-0403360-A2 | Use of phenylethanolamines for the preparation of a medicament for treating ophthalmologic disorders | SANOFI (FR) | 1990-12-19 | — | — | EP | claimed |
| US-4927955-A | Process for the O-alkylation of N-(hydroxy)aralkylphenylethanolamines | SANOFI (FR) | 1990-05-22 | — | — | US | claimed |
| EP-0303546-A2 | O-alkylation process for N-(hydroxy)aralkyl phenyl ethanol amines | SANOFI (FR) | 1989-02-15 | — | — | EP | claimed |
| EP-0966276-B1 | USE OF BETA-3 ADRENERGIC RECEPTOR AGONISTS FOR PREPARING WOUND-HEALING PHARMACEUTICALS | SANOFI SYNTHELABO (FR) | 2003-12-10 | — | — | EP | disclosed |
| US-6235793-B1 | IN DIABETIC MAMMALS | SANOFI-SYNTHELABO (FR) | 2001-05-22 | — | — | US | disclosed |
| EP-0403360-B1 | Use of phenylethanolamines for the preparation of a medicament for treating ophthalmologic disorders | SANOFI SA (FR) | 1996-10-16 | — | — | EP | disclosed |
| EP-0489640-B1 | Use of phenylethanolaminotetralines for preparing antidepressant and anti-stress medicines | SANOFI SA (FR) | 1996-10-02 | — | — | EP | disclosed |
| EP-0303546-B1 | O-alkylation process for N-(hydroxy)aralkyl phenyl ethanol amines | SANOFI SA (FR) | 1994-12-28 | — | — | EP | disclosed |
| US-5236951-A | Administering a phenylethanolamine derivative | SANOFI (FR) | 1993-08-17 | — | — | US | disclosed |
| US-5041606-A | Process for the O-alkylation of N-(hydroxy)aralkylphenylethanolamines | SANOFI | 1991-08-20 | — | — | US | disclosed |
| EP-0403360-A2 | Use of phenylethanolamines for the preparation of a medicament for treating ophthalmologic disorders | SANOFI (FR) | 1990-12-19 | — | — | EP | disclosed |
| US-4927955-A | Process for the O-alkylation of N-(hydroxy)aralkylphenylethanolamines | SANOFI (FR) | 1990-05-22 | — | — | US | disclosed |
| EP-0303546-A2 | O-alkylation process for N-(hydroxy)aralkyl phenyl ethanol amines | SANOFI (FR) | 1989-02-15 | — | — | EP | disclosed |